Intentional internal high-dose policy in VMAT for stage III NSCLC with consolidation durvalumab: a retrospective study

BACKGROUND: Concurrent chemoradiotherapy followed by durvalumab is the standard of care for unresectable stage III non-small cell lung cancer (NSCLC). However, uniform radiation dose escalation has failed to improve outcomes due to increased toxicity. The intentional internal high dose policy (IIHDP...

Disgrifiad llawn

Manylion Llyfryddiaeth

Prif Awduron:	Kae Okuma, Tairo Kashihara, Yuko Nakayama, Koji Inaba, Tomoya Kaneda, Kana Takahashi, Madoka Sakuramachi, Ayaka Nagao, Akane Yoshiba, Hiroshi Igaki
Fformat:	Artigo
Iaith:	Inglês
Cyhoeddwyd:	Via Medica 2026-02-01
Cyfres:	Reports of Practical Oncology and Radiotherapy
Pynciau:	NSCLC intentional internal high dose policy (IIHDP) volumetric modulated arc therapy (VMAT) durvalumab radiation dose escalation local control toxicity
Mynediad Ar-lein:	https://journals.viamedica.pl/rpor/article/view/110097
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!